• Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD1,2
     
  • Follows establishment of multi-disciplinary expert coalition and Novartis commitment to sharing data and findings with ophthalmology community
     
  • Despite existing therapies, significant unmet need still exists for wet AMD patients; data shows around half of patients have unresolved fluid, with a third requiring monthly injections3,4             

Basel, November 13, …

  •  Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult patients and in three age categories1,2

  • Sustained LDL-C reduction with inclisiran was observed regardless of age or gender differences1,2 with two doses a year, after an initial dose and then again at three months; the overall …

Cell samples from COVID19 lung tissue analysis

Translational immunologists from the Novartis Institutes for BioMedical …

  • The Phase III trial investigating canakinumab plus standard of care (SoC) did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical ventilation, or its key secondary endpoint of reduced COVID-19 mortality, compared with SoC1

  • Ilaris® (canakinumab) remains an effective …
  • Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx®  at Week 12  vs. placebo, with improvements as early as Week 11
     
  • ULTIMATE is the first ever Phase IIIb imaging study primarily looking at the time course of response to Cosentyx in biologic-naïve patients with active psoriatic arthritis (PsA) using Power Doppler ultrasonography (PDUS)1
     
  • PDUS is a sensitive technology, allowing detection and monitoring of early changes in synovitis and enthesitis1

If you took all the people on Earth with atherosclerosis and moved them to a single country, it would be the most populous nation on the planet. Those relocated would wonder why they were chosen, because their condition – caused by high cholesterol – is invisible.

It is also potentially deadly.

Atherosclerosis, caused by a buildup of cholesterol that forms plaques in arteries, increases the risk of cardiovascular disease, such as a heart attack and stroke. Despite the availability of approved medicines, heart disease remains the No. 1 cause of death by chronic disease worldwide …

  • The first randomized, double blind, head-to-head study of Aimovig® (erenumab) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and secondary endpoints
  • Aimovig showed superior tolerability and efficacy against topiramate and provided a significant reduction in monthly migraine days (MMDs)
  • Aimovig is the most prescribed anti-calcitonin gene-related peptide pathway (anti-CGRP) …